|
Jul 25
|
Biotech Is Booming, and This Undervalued REIT Stands to Gain
|
|
Jul 25
|
Stocks to watch next week: Microsoft, Apple, Shell, AstraZeneca and HSBC
|
|
Jul 25
|
Moderna (MRNA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
|
|
Jul 25
|
EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's COVID-19 mRNA Vaccine Targeting the SARS-CoV-2 Variant LP.8.1
|
|
Jul 24
|
Moderna (MRNA) Stock Slides as Market Rises: Facts to Know Before You Trade
|
|
Jul 22
|
Rivian, Wayfair, and 7 More Stocks That Could Join the Meme Trade
|
|
Jul 21
|
BizTrip.AI Launches Agentic AI Assistant to Revolutionize Corporate Travel Booking and Management
|
|
Jul 18
|
Here's Why Moderna (MRNA) Fell More Than Broader Market
|
|
Jul 18
|
Moderna, Lantheus, Centene, AMN Healthcare Services, and NeoGenomics Shares Plummet, What You Need To Know
|
|
Jul 18
|
How IBM and Moderna’s partnership could lead to an explosion in drug development
|
|
Jun 27
|
Cancer Vaccine (Preventative, Therapeutic) Market Research 2025 with Analyst Recommendations-Leveraging AI and Bioinformatics for Precision Development / Pursue Fast-Track and Orphan Drug Designations
|
|
Jun 26
|
Moderna (MRNA) Outperforms Broader Market: What You Need to Know
|
|
Jun 26
|
The Top 5 Analyst Questions From Moderna’s Q1 Earnings Call
|
|
Jun 25
|
Seeking a Cure for Sickly Corporate Governance at SinoVac
|
|
Jun 25
|
Moderna (MRNA): Buy, Sell, or Hold Post Q1 Earnings?
|
|
Jun 24
|
Moderna, Inc. (MRNA): A Bull Case Theory
|
|
Jun 24
|
Moderna RSV Vaccine Gains Expanded FDA Approval for Younger Adults
|
|
May 16
|
S&P 500 Gains & Losses Today: Index Notches 5-Day Win Streak Despite Consumer Sentiment Slide
|
|
May 16
|
Was Jim Cramer Right About Moderna (MRNA) Stock?
|
|
May 16
|
Moderna (NasdaqGS:MRNA) Begins Phase 1 Study on Novel Cancer Therapy Candidate
|